Black Samantha, Zulliger Rose, Marcus Rebecca, Mark Daniella, Myer Landon, Bekker Linda-Gail
a Desmond Tutu HIV Centre, Institute of Infectious Diseases & Molecular Medicine , University of Cape Town , Cape Town , South Africa.
AIDS Care. 2014;26(6):736-41. doi: 10.1080/09540121.2013.855300. Epub 2013 Nov 7.
Maternal antiretroviral therapy (ART) is a critical intervention in the prevention-of-mother-to child transmission (PMTCT) of HIV. In South Africa, many HIV-infected pregnant women commence ART late in pregnancy, and as a result, the duration of ART prior to delivery is often insufficient to prevent vertical transmission. To address this, we designed an intervention for the rapid initiation of ART in pregnancy (RAP), where patient's ART preparation occurred during rather than before treatment commencement. Here we report on the acceptability and the challenges of the RAP programme. We conducted 7 key informant and 27 semi-structured interviews with RAP participants. Participants were purposefully selected based on ART-eligibility and stage in the pregnancy to post-partum continuum. Interviews were conducted in participants' home language by trained fieldworkers, with key informant interviews conducted by the study investigators. The data were analysed using a framework analysis approach. Rapid initiation in pregnancy was acceptable to the majority of programme participants and protection of the woman's unborn child was the primary motivation for starting treatment. The key barrier was the limited time to accept the dual challenges of being diagnosed HIV-positive and eligible for life-long ART. Truncated time also limited the opportunity for disclosure to others. Despite these and other barriers, most women found the benefits of rapid ART commencement outweighed the challenges, with 91% of women initiated onto ART starting the same day treatment eligibility was determined. Many participants and key informants identified the importance of counseling and the need to make an informed, independent choice on the timing of ART initiation, based on individual circumstances. Acceptance of ART-eligibility improved with time on the programme, however, as women's principal reason for initiating ART was protection of the unborn child, monitoring and supporting adherence during the post-partum period will be critical.
孕产妇抗逆转录病毒疗法(ART)是预防艾滋病毒母婴传播(PMTCT)的一项关键干预措施。在南非,许多感染艾滋病毒的孕妇在孕期晚期才开始接受抗逆转录病毒疗法,因此,分娩前接受抗逆转录病毒疗法的时间往往不足以预防垂直传播。为解决这一问题,我们设计了一种孕期快速启动抗逆转录病毒疗法(RAP)的干预措施,即患者的抗逆转录病毒疗法准备工作在治疗开始期间而非之前进行。在此,我们报告RAP项目的可接受性和挑战。我们对RAP参与者进行了7次关键信息人访谈和27次半结构化访谈。根据抗逆转录病毒疗法资格和孕期至产后连续过程中的阶段,有目的地选择参与者。访谈由经过培训的现场工作人员用参与者的母语进行,关键信息人访谈由研究调查人员进行。使用框架分析方法对数据进行分析。孕期快速启动疗法为大多数项目参与者所接受,保护妇女未出生的孩子是开始治疗的主要动机。关键障碍是接受艾滋病毒检测呈阳性并符合终身抗逆转录病毒疗法资格这一双重挑战的时间有限。时间缩短也限制了向他人透露病情 的机会。尽管存在这些及其他障碍,但大多数女性认为快速开始抗逆转录病毒疗法的益处大于挑战,91%符合治疗资格的女性在确定资格的同一天就开始接受抗逆转录病毒疗法。许多参与者和关键信息人都认识到咨询的重要性,以及根据个人情况就开始抗逆转录病毒疗法的时机做出明智、独立选择的必要性。随着参与项目时间的推移,对符合抗逆转录病毒疗法资格的接受度有所提高,然而,由于女性开始抗逆转录病毒疗法的主要原因是保护未出生的孩子,因此产后期间监测和支持依从性将至关重要。